Topline results from the phase 3 HERIZON-GEA-01 trial show that the HER2-targeted bispecific antibody zanidatamab-hrii ...
Dr. Christian S. Hinrichs discusses the future of specialized cell therapies, predicting broader access for community clinics similar to CAR T cell treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback